2 weeks Ago By Defense World Staff
Rhumbline Advisers reduced its holdings in Seer, Inc. ( NASDAQ:SEER – Free Report ) by 67.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor owned 28,885 shares of the company’s stock after selling 59,140 shares during the period. Rhumbline Advisers’ holdings in Seer were worth $49,000 at the end of the most recent reporting period. A number of other institutional investors have also recently bought and sold shares of the business.
Kent Lake Capital LLC acquired a new stake in shares of Seer during the 1st quarter valued at $1,425,000. Price T Rowe Associates Inc. MD boosted its position in Seer by 74.
5% during the first quarter. Price T Rowe Associates Inc. MD now owns 59,580 shares of the company’s stock valued at $114,000 after purchasing an additional 25,441 shares during the last quarter.
Quadrature Capital Ltd purchased a new position in Seer in the first quarter valued at about $56,000. Acadian Asset Management LLC increased its position in Seer by 233.7% in the 1st quarter.
Acadian Asset Management LLC now owns 1,329,823 shares of the company’s stock worth $2,525,000 after purchasing an additional 931,260 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Seer by 1.
0% during the 1st quarter. Vanguard Group Inc. now owns 2,636,577 shares of the company’s stock worth $5,009,000 after purchasing an additional 25,944 shares in the last quarter.
75.20% of the stock is currently owned by institutional investors and hedge funds. Seer Price Performance Seer stock opened at $1.
97 on Tuesday. Seer, Inc. has a fifty-two week low of $1.
46 and a fifty-two week high of $2.30. The firm has a fifty day moving average price of $1.
75 and a two-hundred day moving average price of $1.81. The firm has a market cap of $127.
60 million, a price-to-earnings ratio of -1.52 and a beta of 1.44.
Analyst Ratings Changes Separately, Morgan Stanley lowered their price target on Seer from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 13th.
Get Our Latest Report on Seer Seer Profile ( Free Report ) Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. Recommended Stories Five stocks we like better than Seer Dividend Payout Ratio Calculator TJX Stock: A Buying Opportunity Before the Holiday Rush Why is the Ex-Dividend Date Significant to Investors? Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge Using the MarketBeat Dividend Tax Calculator Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.
com's FREE daily email newsletter ..
